Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

The global supply of COVID-19 vaccines remains limited. An understanding of the immune
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …

Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…

Nirsevimab to Prevent RSV Illness in Infants Nirsevimab, a monoclonal antibody targeting
respiratory syncytial virus, protected against RSV-associated hospitalization and severe …

Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …

Background Intranasal vaccination may induce protective local and systemic immune responses
against respiratory pathogens. A number of intranasal SARS-CoV-2 vaccine candidates …

The cellular tropisms of eukaryotic viruses are shaped by their need for entry receptors and
intracellular transcription factors. Here we show that viral tropisms can also be regulated by …

AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus–vectored vaccine,
has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 in …